Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Jefferies Sticks to Its Buy Rating for AstraZeneca (AZN)

Tipranks - Tipranks - Wed Apr 1, 5:52AM CDT

In a report released today, Michael Leuchten from Jefferies maintained a Buy rating on AstraZeneca, with a price target of £180.00.

End of Quarter Sale - 50% Off TipRanks

Leuchten covers the Healthcare sector, focusing on stocks such as Novo Nordisk, AstraZeneca, and GlaxoSmithKline. According to TipRanks, Leuchten has an average return of -4.7% and a 50.44% success rate on recommended stocks.

In addition to Jefferies, AstraZeneca also received a Buy from Barclays’s James Gordon CFA in a report issued today. However, yesterday, Deutsche Bank maintained a Sell rating on AstraZeneca (LSE: AZN).

See today’s best-performing stocks on TipRanks >>

Based on AstraZeneca’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p15.5 billion and a net profit of p2.33 billion. In comparison, last year the company earned a revenue of p14.54 billion and had a net profit of p1.46 billion

Read More on GB:AZN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).